Alexander Cohen1, Jay Mandrekar2, Erik K St Louis3, Michael H Silber4, Suresh Kotagal5. 1. Mayo Clinic, Department of Neurology, USA; Boston Children's Hospital, Department of Neurology, USA. Electronic address: Alexander.Cohen2@childrens.harvard.edu. 2. Mayo Clinic, Division of Biomedical Statistics and Informatics, USA. Electronic address: Mandrekar.Jay@mayo.edu. 3. Mayo Clinic, Department of Neurology, USA; Mayo Clinic, Center for Sleep Medicine, USA. Electronic address: StLouis.Erik@mayo.edu. 4. Mayo Clinic, Department of Neurology, USA; Mayo Clinic, Center for Sleep Medicine, USA. Electronic address: msilber@mayo.edu. 5. Mayo Clinic, Department of Neurology, USA; Mayo Clinic, Division of Biomedical Statistics and Informatics, USA; Mayo Clinic, Center for Sleep Medicine, USA; Mayo Clinic, Department of Pediatric and Adolescent Medicine, USA. Electronic address: kotagal.suresh@mayo.edu.
Abstract
STUDY OBJECTIVE: To assess comorbidities in a community-based cohort of narcolepsy. METHODS: A 2000-2014 community-based narcolepsy cohort was identified in Olmsted County, Minnesota. Records were reviewed by a certified sleep specialist for accuracy of diagnosis, and comorbidities were extracted and analyzed. Comorbidities in narcolepsy subjects, both at diagnosis and upon follow-up, were compared with those in unaffected and age- and sex-matched cohort using conditional logistic regression. RESULTS: At diagnosis, there was increased association of narcolepsy with anxiety (OR 4.56, 95% CI 1.99-10.44), thyroid disease (3.07, 1.19-7.90), hypertension (2.69, 1.22-5.93), and hyperlipidemia (2.49, 1.05-5.92). At the end of the prolonged observation period of 9.9 years (SD 7.27 years), there was increased association of narcolepsy with peripheral neuropathy (11.21, 1.16-108.11), non-migrainous headache (6.00, 1.73-20.83), glucose intolerance (2.39, 1.05-5.45), and automobile-related trauma (2.43, 1.08-5.45). Persistently increased both at diagnosis and after a prolonged observation period were associations of narcolepsy with obstructive sleep apnea (OSA) (69.25, 9.26-517.99 decreasing to 13.55, 5.08-36.14), chronic low back pain (5.46, 2.46-12.11 to 2.58, 1.39-4.77), depression (4.88, 2.45-9.73 to 3.79, 2.12-6.79), psychiatric disorders in general (4.73, 2.49-9.01 to 3.40, 1.94-5.98), endocrinopathies (4.15, 1.81-9.56 to 2.45, 1.33-4.49), and obesity (2.27, 1.13-4.56 to 2.07, 1.15-3.7). CONCLUSIONS: In this community-based study of narcolepsy comorbidities, both at diagnosis and after prolonged follow-up, persistent comorbidities were revealed, including OSA, chronic low back pain, psychiatric disorders in general, endocrinopathies, and obesity. The comprehensive management of narcolepsy requires monitoring for and managing these important associated health conditions.
STUDY OBJECTIVE: To assess comorbidities in a community-based cohort of narcolepsy. METHODS: A 2000-2014 community-based narcolepsy cohort was identified in Olmsted County, Minnesota. Records were reviewed by a certified sleep specialist for accuracy of diagnosis, and comorbidities were extracted and analyzed. Comorbidities in narcolepsy subjects, both at diagnosis and upon follow-up, were compared with those in unaffected and age- and sex-matched cohort using conditional logistic regression. RESULTS: At diagnosis, there was increased association of narcolepsy with anxiety (OR 4.56, 95% CI 1.99-10.44), thyroid disease (3.07, 1.19-7.90), hypertension (2.69, 1.22-5.93), and hyperlipidemia (2.49, 1.05-5.92). At the end of the prolonged observation period of 9.9 years (SD 7.27 years), there was increased association of narcolepsy with peripheral neuropathy (11.21, 1.16-108.11), non-migrainous headache (6.00, 1.73-20.83), glucose intolerance (2.39, 1.05-5.45), and automobile-related trauma (2.43, 1.08-5.45). Persistently increased both at diagnosis and after a prolonged observation period were associations of narcolepsy with obstructive sleep apnea (OSA) (69.25, 9.26-517.99 decreasing to 13.55, 5.08-36.14), chronic low back pain (5.46, 2.46-12.11 to 2.58, 1.39-4.77), depression (4.88, 2.45-9.73 to 3.79, 2.12-6.79), psychiatric disorders in general (4.73, 2.49-9.01 to 3.40, 1.94-5.98), endocrinopathies (4.15, 1.81-9.56 to 2.45, 1.33-4.49), and obesity (2.27, 1.13-4.56 to 2.07, 1.15-3.7). CONCLUSIONS: In this community-based study of narcolepsy comorbidities, both at diagnosis and after prolonged follow-up, persistent comorbidities were revealed, including OSA, chronic low back pain, psychiatric disorders in general, endocrinopathies, and obesity. The comprehensive management of narcolepsy requires monitoring for and managing these important associated health conditions.
Authors: Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Mayo Clin Proc Date: 2012-02 Impact factor: 7.616
Authors: Raquel N Taddei; Esther Werth; Rositsa Poryazova; Christian R Baumann; Philipp O Valko Journal: J Sleep Res Date: 2016-05-06 Impact factor: 3.981
Authors: Mary C Kapella; Barbara E Berger; Boris A Vern; Sachin Vispute; Bharati Prasad; David W Carley Journal: PLoS One Date: 2015-04-21 Impact factor: 3.240
Authors: Christian Franceschini; Chiara Fante; Maria Claudia Folli; Maria Filosa; Fabio Pizza; Elena Antelmi; Francesca Ingravallo; Giuseppe Plazzi Journal: J Clin Sleep Med Date: 2020-04-15 Impact factor: 4.062
Authors: Bhanu Prakash Kolla; Marjan Jahani Kondori; Michael H Silber; Hala Samman; Swati Dhankikar; Meghna P Mansukhani Journal: J Clin Sleep Med Date: 2020-11-15 Impact factor: 4.062